An observational study in Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC) and Ascites, Malignant, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Zhejiang Cancer Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Stomach Neoplasms by Zhejiang Cancer Hospital — 10 open to participants now, 13 under way, none of them phase 3. Stomach Neoplasms · Zhejiang Cancer Hospital.
Among the 25 studies in Stomach Neoplasms by Zhejiang Cancer Hospital, this one is one of 3 that started in 2026, is one of 9 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 24th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 25 studies in Stomach Neoplasms by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Zhejiang Cancer Hospital · Sites in China
Ages 18–75
Zhejiang Cancer Hospital · Sites in China
Ages 18–75
Zhejiang Cancer Hospital · Sites in China
Ages 18–90 · Healthy volunteers
Zhejiang Cancer Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 43 across the 16 interventional studies, 480 across the 9 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zhejiang Cancer Hospital is the lead sponsor of 282 studies on the registry; 117 are open to participants now.
1 of the studies in Stomach Neoplasms by Zhejiang Cancer Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07067983Zhejiang Cancer HospitalClinical Evaluation of GRAPE Model for Gastric Cancer Screening | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Stomach Neoplasms by Zhejiang Cancer Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric or gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites. The study will also explore potential predictive biomarkers of treatment response through longitudinal collection and multi-omics analysis of tumor tissue, peripheral blood, and ascites.
Peritoneal metastasis is common in advanced gastric cancer and is associated with malignant ascites and poor prognosis. The efficacy of anti-PD-1 therapy combined with chemotherapy in this population remains insufficiently characterized, and reliable predictive biomarkers are lacking. This prospective, single-center, observational study conducted in China plans to enroll approximately 50 patients with previously untreated, unresectable advanced or metastatic gastric or gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites. Patients will receive anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment.
Clinical efficacy and safety will be evaluated using ascites objective response rate, progression-free survival, overall survival, 12-month overall survival rate, and treatment-related adverse events. Tumor tissue, peripheral blood, and ascites will be collected at baseline, prior to Cycle 2 or Cycle 3 of treatment, and at disease progression when available. Multi-omics analyses, including single-cell transcriptomics, spatial transcriptomics, proteomics, metabolomics, flow cytometry, and related assays, will be performed to identify potential predictive biomarkers and explore an integrated model for predicting treatment response.
Patients with previously untreated, unresectable advanced or metastatic gastric or gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites. Eligible patients will receive first-line anti-PD-1 immunotherapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Have fully understood the study and voluntarily signed the form (ICF); confirmed gastric adenocarcinoma or gastroesophageal junction (GC/GEJ) adenocarcinoma with unresectable advanced or disease; -negative and mismatch repair-proficient (pMMR); Moderate or greater volume of ascites at baseline; Peritoneal metastasis confirmed by ascites cytology or laparoscopy; Aged 18 to 75 years, regardless of sex; Receiving immunotherapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel.
Exclusion Criteria:
- History of or concurrent active other than gastric cancer within the past 5 years; Previous systemic treatment for unresectable advanced or GC/GEJ adenocarcinoma.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with untreated advanced or metastatic GC/GEJ adenocarcinoma with malignant ascites receiving first-line anti-PD-1 therapy plus systemic chemotherapy and intraperitoneal nab-paclitaxel.
Ascites objective response rate (ORR)
The ascites objective response rate (ORR) was calculated as a summed ratio of patients with disappeared and decreased ascites to the total number of patients.
Time frame: 1 year
Overall Survival (OS)
OS is calculated from diagnosis to death or last follow-up time
Time frame: 1 year
Progress free survival (PFS)
PFS is defined as the time from the date of treatment to the first date of disease
Time frame: 1 year
12 months os rate
The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months
Time frame: 1 year
Safety assessment
Number and percentage of participants with Adverse Events (any Grade and Grade 3/4)
Time frame: 1 year
Dynamics of Peripheral Blood Biomarkers
Changes in blood-based biomarker levels will be measured. Peripheral blood samples will be used for: 1) Immunophenotyping: The frequency of key immune cell subsets (e.g., CD4+/CD8+ T cells) in PBMCs will be analyzed by flow cytometry and single-cell transcriptome sequencing. 2) Plasma Multi-omics: Proteins and metabolites will be profiled using proteomics and metabolomics platforms, respectively. Metrics will include the mean change from baseline at each timepoint and the correlation of these changes with clinical response.
Time frame: Baseline; prior to Cycle 2 or Cycle 3 of treatment; and at documented disease progression, assessed up to 24 months
Biomarkers in Tumor Tissue
tumor tissue samples will be used for: 1) Immunophenotyping: The frequency of multiple cell subsets in fresh tumors will be analyzed by single-cell transcriptome sequencing. 2) Paraffin sections: used for immunohistochemistry and immunofluorescence. Data will include the mean change from baseline at each timepoint and the correlation of these changes with clinical response.3)Single-cell transcriptome sequencing.
Time frame: Baseline; prior to Cycle 3 of treatment; and at documented disease progression, assessed up to 24 months
Dynamics of Ascites Biomarkers
Changes in ascites-based biomarker levels will be measured. Ascites samples will be used for: 1) Cell clustering: The frequency of multiple cell subsets in ascites will be analyzed by flow cytometry and single-cell transcriptome sequencing. 2) ascites multi-omics: Proteins and metabolites of ascites supernatant will be profiled using ELISA, proteomics, metabolomics platforms, and etc. Metrics will include the mean change from baseline at each timepoint and the correlation of these changes with clinical response.
Time frame: Baseline; prior to Cycle 2 or Cycle 3 of treatment; and at documented disease progression, assessed up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 24 months is below that.
Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.